<DOC>
	<DOC>NCT02982005</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis randomized in a double-blind manner to receive KHK4827 or placebo for 12 weeks</brief_summary>
	<brief_title>A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject has had stable moderate to severe plaque psoriasis for at least 6 months Subject has involved BSA ≧ 10%, PASI ≧ 12, and sPGA ≧ 3 at screening and at baseline Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, or a medicationinduced psoriasis, or other skin conditions (e.g., eczema) at screening that would interfere with study evaluations Subject scheduled to undergo a surgical intervention during the study period Subject has any active infection or history of infections as defined in the study protocol Subject has known history of Crohn's disease Subject has any other significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol Subject has not stopped using certain psoriasis therapies as defined in the study protocol Subject has previously used any antiIL17 biologic therapy Subject is pregnant or breast feeding, or planning to become pregnant while enrolled in the study Women of childbearing potential or fertile men who do not agree to use effective contraception from the day of providing consent through 12 weeks after the last dose of investigational product. Subject has known history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the ColumbiaSuicide Severity Rating Scale (CSSRS) at screening or at baseline Subject has severe depression based on a total score of ≥ 15 on the Patient Health Questionnaire8 (PHQ8) at screening or at baseline Subject has known history or evidence of a psychiatric disorder that, in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion Subject has known history of alcohol and/or substance abuse within the last 12 months"</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>KHK4827 (brodalumab)</keyword>
</DOC>